Skip to main content

Press releases | February 24, 2021

Fried Frank acted as counsel to BofA as financial advisor to PRA Health Sciences (“PRA”) in its approximately US$12b acquisition by ICON plc (“ICON”). ICON is a global provider of outsourced drug and device development and commercialization services to the pharmaceutical, biotechnology and medical device industries. PRA is a global contract research organization, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. ICON intends to fund the cash portion of the transaction consideration through a combination of cash on hand and fully committed debt financing from Citi. The transaction is not subject to a financing condition and is anticipated to close during quarter three of 2021.  

The Fried Frank team was led by corporate partner Philip Richter and included corporate partner Roy Tannenbaum and corporate associate Natalia Caruso.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.